Drug Trial Radar · NCT01327053
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Aug 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
230
Actual
Start
Jun 29, 2011
Primary completion
Jun 28, 2013
Study completion Jun 29, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.
Conditions
- Basal Cell Carcinoma
Interventions
LDE225Drug
LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)Time frame: 6 months
- Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)Time frame: 6 months
Locations
62 sites in 12 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Fayetteville, Arkansas
University of California at Los Angeles UCLA 3
Los Angeles, California
Stanford University Medical Center Stanford Univ 2
Stanford, California
University of Colorado School of Medicine UC
Aurora, Colorado
Washington Hospital Center Wash Hospital
Washington D.C., District of Columbia
H Lee Moffitt Cancer Center and Research Institute Cutaneous Onc Dept
Tampa, Florida
NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Study coordinator
Chicago, Illinois
Dana Farber Cancer Institute DFCI - MA
Boston, Massachusetts
Henry Ford Hospital Henry Ford
Detroit, Michigan
Washington University School Of Medicine-Siteman Cancer Ctr Siteman
St Louis, Missouri
Comprehensive Cancer Centers of Nevada CCC of Nevada- Southwest (2)
Las Vegas, Nevada
Hackensack University Medical Center Hackensack (SC)
Hackensack, New Jersey
New York University Medical Center SC-2
New York, New York
Penn State University / Milton S. Hershey Medical Center Hershey Medical
Hershey, Pennsylvania
University of Pittsburgh Medical Center UPMC
Pittsburgh, Pennsylvania
Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology
Dallas, Texas
Texas Oncology Tex Onc 3
Dallas, Texas
Texas Oncology Texas Onc - Amarillo
Dallas, Texas
University of Texas MD Anderson Cancer Center MD Anderson
Houston, Texas
Texas Oncology Cancer Care & Research Center
Waco, Texas
Texoma Cancer Center Texoma Cancer Center
Wichita Falls, Texas
University of Utah / Huntsman Cancer Institute Huntsman/Univ UT
Salt Lake City, Utah
Novartis Investigative Site
St Leonards, New South Wales, Australia
Novartis Investigative Site
Geelong, Victoria, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Wilrijk, Belgium
Novartis Investigative Site
Waterloo, Ontario, Canada
Novartis Investigative Site
Sainte-Foy, Quebec, Canada
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Pierre-Bénite, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Gera, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Kiel, Germany
Novartis Investigative Site
Mainz, Germany
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.